Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia

Respirology

Volumn 21, Issue 8, 2016, Pages 1431-1437

  Arai, Toru ^a   Kagawa, Tomoko ^a   Sasaki, Yumiko ^a   Sugawara, Reiko ^a   Sugimoto, Chikatoshi ^a   Tachibana, Kazunobu ^a   Kitaichi, Masanori ^a,b   Akira, Masanori ^a   Hayashi, Seiji ^a   Inoue, Yoshikazu ^a  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b National Hospital Organizaton Minami Wakayama Medical Center   (Japan)

Author keywords

acute exacerbation; high resolution computed tomography; idiopathic interstitial pneumonia; idiopathic pulmonary fibrosis; usual interstitial pneumonia

Indexed keywords

ACUTE EXACERBATION; ADULT; AGE; AGED; ARTICLE; BODY MASS; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; FEMALE; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTED TOMOGRAPHY; HUMAN; INCIDENCE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG DIFFUSION CAPACITY OF CARBON MONOXIDE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH COUNCIL; PRACTICE GUIDELINE; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE ASSESSMENT; RETROSPECTIVE STUDY; SURVIVAL; BIOPSY; FIBROSING ALVEOLITIS; JAPAN; LUNG; LUNG FUNCTION TEST; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; X-RAY COMPUTED TOMOGRAPHY;

AGED; BIOPSY; FEMALE; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; JAPAN; LUNG; MALE; MIDDLE AGED; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SYMPTOM FLARE UP; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84991475486     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12862     Document Type: Article

References (31)

1. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949–61.
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.
3. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Jr, Lasky JA, Loyd JE, Noth I, Olman MA et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2007; 176: 636–43.
4. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur. Respir. J. 2006; 27: 143–50.
5. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993; 103: 1808–12.
6. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G et al. IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann. Intern. Med. 2005; 142: 963–7.
7. Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am. J. Roentgenol. 1997; 168: 79–83.
8. Akira M, Kouzaka T, Yamamoto S, Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008; 178: 372–8.
9. Tachibana K, Inoue Y, Nishiyama A, Sugimoto C, Matsumuro A, Hirose M, Kitaichi M, Akira M, Arai T, Hayashi S et al. Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: serum IL-7 as a prognostic marker. Sarcoidosis Vasc. Diffuse Lung Dis. 2011; 28: 113–22.
10. Kondoh H, Taniguchi H, Katsuta T, Kataoka K, Nishiyama O, Sakamoto K, Johkoh T, Nishimura M, Ono K, Kitaichi M. Risk of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2010; 27: 103–10.
11. Song JW, Hong S-B, Lim C-M, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur. Respir. J. 2011; 37: 356–63.
12. Park IN, Kim DS, Shim TS, Lim C-M, Lee SD, Koh Y, Kim WS, Kim WD, Jang SJ, Colby TV. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 2007; 132: 214–20.
13. Miyazaki Y, Tateishi T, Akashi T, Ohtani Y, Inase N, Yoshizawa Y. Clinical predictor s and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis. Chest 2008; 134: 1265–70.
14. Tachikawa R, Tomii K, Ueda H, Nagata K, Nanjo S, Sakurai A, Otsuka K, Kaji R, Hayashi M, Katakami N et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic. Respiration 2012; 83: 20–7.
15. Travis WD, Costabel U, Hansel DM, King TE, Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733–8.
16. Neurohr C, Behr J. Change in the current classification of IIP: a critical review. Respirology 2015; 20: 699–704.
17. Taniguchi H, Ebina Y, Kondoh T, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. A phase III clinical trail in Japan. Online supplement. Eur. Respir. J. 2010; 35: 821–9.
18. Celli BR, MacNee W ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 2004; 23: 932–46.
19. Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois EM, Drent M, Haslam PL, Kim DS, Nagai S et al. American Thoracic Society Committee on BAL in Interstitial Lung Disease. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am. J. Respir. Crit. Care Med. 2012; 185: 1004–14.
20. Sumikawa H, Johkoh T, Fujimoyo K, Arakawa H, Colby TV, Fukuoka J, Taniguchi H, Kondoh Y, Kataoka K, Ogura T et al. Pathologically proved nonspecific interstitial pneumonia: CT pattern analysis as compared with usual interstitial pneumonia CT pattern. Radiology 2014; 272: 549–56.
21. Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, Travis WD, Mumford JA, Murray S, Flint A et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58: 143–8.
22. Raghu G, Lynch D, Godwin JD, Webb R, Colby TV, Leslie KO, Behr J, Brown KK, Egan JJ, Flaherty KR et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir. Med. 2014; 2: 277–84.
23. Daniels CE, Yi ES, Ryu JH. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2008; 32: 170–4.
24. Jeong YJ, Lee KS, Muller NL, Chung MP, Chung MJ, Han J, Colby TV, Kim S. Usual interstitial pneumonia and non-specific interstitial pneumonia serial thin-section CT findings correlated with pulmonary function. Korean J. Radiol. 2005; 6: 143–52.
25. Lee JW, Shehu E, Gjonbrataj BYE, Rho BH, Lee M-Y, Choi W-I. Clinical findings and outcomes in patients with possible usual interstitial pneumonia. Respir. Med. 2015; 109: 510–6.
26. Usui Y, Kaga A, Sakai F, Shiono A, Komiyama K, Hagiwara K, Kanazawa M. A cohort of mortality predictors in patients with acute exacerbation of chronic fibrosing interstitial pneumonia. BMJ Open 2013; 3: e002971.
27. Ohshimo S, Ichikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, Kohno N, Bonella F, Guzman J, Costabel U. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir. Med. 2014; 108: 1031–9.
28. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE Jr. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135: 1557–63.
29. Plönes T, Osei-Agyemang T, Elze M, Palade E, Wagnetz D, Loop T, Kayser G, Passlik B. Morbidity and mortality in patients with usual interstitial pneumonia (UIP) pattern undergoing surgical lung biopsy. Respir. Med. 2013; 107: 629–32.
30. Roto N, Imperatori A, Dominioni L, Facchini A, Conti V, Castiglioni M, Spanevello A. Efficacy and safety of surgical lung biopsy for interstitial disease. Experience of 161 consecutive patients from a single institute in Italy. Sarcoidosis Vasc. Diffuse Lung Dis. 2015; 32: 251–8.
31. Ohshimo S, Bonella F, Ai C, Beume M, Kohno N, Guzman J, Costabel U. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179: 1043–7.